95 results
8-K
EX-99.1
STRO
Sutro Biopharma Inc
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
safety and anti-tumor activity data from our Phase 1 clinical trial for STRO-002, including data presented during the AACR Virtual Meeting on April 27 … in a heavily pre-treated patient population along with an emerging safety profile that indicates that the product candidate is generally well tolerated
8-K
EX-99.1
STRO
Sutro Biopharma Inc
8 Jan 24
Results of Operations and Financial Condition
7:31am
with partial hematologic recovery (CRh) rate EFS, RFS and OS Safety, PK Selected Dose N = ~18 PRV: Pediatric Review Voucher Sources … analysis for full approval: PFS, OS Interim analysis planned to support accelerated approval: ORR, DOR Safety, QoL, PK Optimized Dose Regimen
DRSLTR
STRO
Sutro Biopharma Inc
10 Jul 18
Correspondence regarding draft registration statement
12:00am
, 107 and 111 of Draft No. 2 to clarify that additional studies will be needed to determine the safety and efficacy of the Company’s product candidates … greater anti-tumor activity, stability and safety than competing therapies. The Company also believes that STRO-001 has the potential to be first-in-class
8-K
EX-99.1
STRO
Sutro Biopharma Inc
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
. We continue to be encouraged by the dose escalation safety and anti-tumor activity data from our Phase 1 clinical trial for STRO-002, including data … pre-treated patient population, along with an emerging safety profile that indicates that the product candidate has been generally well tolerated
8-K
EX-99.1
STRO
Sutro Biopharma Inc
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
Exhibit 99.1
Sutro Biopharma Reports Third Quarter 2019 Financial Results
and Recent Business Highlights and Developments
STRO-002 Initial Safety … and nine months ended September 30, 2019.
“In late October 2019, we presented encouraging interim safety data from our Phase 1 trial for STRO-002
8-K
EX-99.1
dvf1t n5mlr
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
EX-99.1
41lsr81y395h8nqg
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.1
3kmunl4p7ih
14 Aug 19
Sutro Biopharma Reports Second Quarter 2019 Financial Results
12:00am
8-K
EX-99.2
u20j0c
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
8-K
EX-99.1
gd5g9h6n25 ns1f9j
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.2
vmvgy9g wu3h1k8
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
ku99s yuvvmd9ubpc96
16 Jun 22
Other Events
7:00am
8-K
EX-99.1
w20fntz
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
gltewzga43
15 May 19
Sutro Biopharma Reports First Quarter 2019 Financial Results
7:00am
8-K
EX-99.2
5vhffbf17gtcjtze3m1f
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.2
aozxfyvxt 2clprufpu5
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
10-K
a3soihox
1 Apr 19
Annual report
12:00am
8-K
EX-99.1
oq7tlnch8ok5lrv
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm